Coverage is subject to the terms, conditions, and limitations of the member's contract.
Although the US Food and Drug Administration (FDA) has approved devices for bioimpedance for the detection of lymphedema, the Company has determined that the effectiveness of this procedure cannot be established by review of the available published peer-reviewed literature. Therefore, bioimpedance for the detection of lymphedema is considered experimental/investigational by the Company and not covered.